Luger, Thomas A.
Hebert, Adelaide A. http://orcid.org/0000-0002-9167-5729
Zaenglein, Andrea L.
Silverberg, Jonathan I.
Tan, Huaming
Ports, William C.
Zielinski, Michael A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
https://doi.org/10.1007/s40272-021-00490-y
Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
https://doi.org/10.1007/s13555-021-00509-9
Documents that mention this clinical trial
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
https://doi.org/10.1007/s40272-021-00490-y
Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
https://doi.org/10.1007/s13555-021-00509-9
Funding for this research was provided by:
Pfizer Inc.
Article History
Accepted: 19 December 2021
First Online: 16 March 2022
Declarations
:
: This study was funded by Pfizer Inc.
: Thomas A. Luger has served as an investigator for Pfizer, AbbVie, Celgene, Eli Lilly, LEO Pharma, Menlo Therapeutics, Novartis, and Sandoz; served as a member of scientific advisory boards for Pfizer, AbbVie, Argenx, Celgene, Ceres Pharma, Galderma, Eli Lilly, Janssen-Cilag, La Roche-Posay, LEO Pharma, Menlo Therapeutics, Mylan/Meda AB, Novartis, Pierre Fabre, Piqur Therapeutics, Sandoz, Sanofi-Aventis, and Symrise; and has received funding from Pfizer, AbbVie, Celgene, Janssen-Cilag, Merck Sharp & Dohme, Mylan/Meda AB, Novartis, and Wolff Laboratories. Adelaide A. Hebert discloses that research funding was paid to UTHealth McGovern Medical School from Pfizer, Anacor, Arcutis, Cutanea, Brickell, Dermira, GlaxoSmithKline, and Novan. She has received honoraria as a member of data safety monitoring boards for Bausch, GlaxoSmithKline, and Regeneron-Sanofi and has received honoraria from Pfizer, Biofrontera, Cutanea, Dermavant, Dermira, Galderma, Eli Lilly, Leo Pharma, Ortho Dermatologics, Pierre Fabre, and Verrica. Andrea L. Zaenglein has served as an investigator for AbbVie, Arcutis, Dermavant, Incyte, and Pfizer and as a consultant for Cassiopea and Verrica. Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, and Regeneron-Sanofi; as a consultant for Pfizer, AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermira, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. Huaming Tan and Michael A. Zielinski are employees of and stockholders in Pfizer Inc. William C. Ports was an employee of and stockholder in Pfizer Inc. at the time of this analysis.
: Upon request and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the USA and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.
: Not applicable.
: This study was approved by the local medical ethical committee, and all data were processed anonymously, according to privacy legislation. All parent(s)/legal guardian(s) provided written informed consent. This study was conducted in compliance with ethical principles originating in the Declaration of Helsinki and in compliance with the International Committee on Harmonisation and Good Clinical Practice Guidelines.
: All parent(s) or legal guardian(s) provided written informed consent.
: Not applicable.
: Thomas A. Luger, Adelaide A. Hebert, Andrea L. Zaenglein, Jonathan I. Silverberg, William C. Ports, and Michael A. Zielinski contributed to the conception and design of the analysis, the interpretation of the data, and the drafting and revision of the manuscript. Huaming Tan carried out the analysis and contributed to the interpretation of the data and the drafting and revision of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.